248 related articles for article (PubMed ID: 25139846)
1. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
[TBL] [Abstract][Full Text] [Related]
2. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Shah NP; Lee FY; Luo R; Jiang Y; Donker M; Akin C
Blood; 2006 Jul; 108(1):286-91. PubMed ID: 16434489
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C; DeRemer DL; Akin C
Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
[TBL] [Abstract][Full Text] [Related]
5. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
7. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
[TBL] [Abstract][Full Text] [Related]
8. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
Aichberger KJ; Mayerhofer M; Gleixner KV; Krauth MT; Gruze A; Pickl WF; Wacheck V; Selzer E; Müllauer L; Agis H; Sillaber C; Valent P
Blood; 2007 Apr; 109(7):3031-41. PubMed ID: 17110460
[TBL] [Abstract][Full Text] [Related]
9. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
10. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
11. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.
Chan EC; Bai Y; Kirshenbaum AS; Fischer ER; Simakova O; Bandara G; Scott LM; Wisch LB; Cantave D; Carter MC; Lewis JC; Noel P; Maric I; Gilfillan AM; Metcalfe DD; Wilson TM
J Allergy Clin Immunol; 2014 Jul; 134(1):178-87. PubMed ID: 24582309
[TBL] [Abstract][Full Text] [Related]
12. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
[TBL] [Abstract][Full Text] [Related]
13. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
14. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
Nakagomi N; Hirota S
Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
16. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
[No Abstract] [Full Text] [Related]
17. Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib.
Zhao DD; Zhang L; Li WQ; Duan MH; Zhuang JL; Zhou DB
Chin Med J (Engl); 2019 Aug; 132(16):2002-2003. PubMed ID: 31335472
[No Abstract] [Full Text] [Related]
18. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Gleixner KV; Mayerhofer M; Aichberger KJ; Derdak S; Sonneck K; Böhm A; Gruze A; Samorapoompichit P; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Blood; 2006 Jan; 107(2):752-9. PubMed ID: 16189265
[TBL] [Abstract][Full Text] [Related]
19. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
Zhang LY; Smith ML; Schultheis B; Fitzgibbon J; Lister TA; Melo JV; Cross NC; Cavenagh JD
Leuk Res; 2006 Apr; 30(4):373-8. PubMed ID: 16183119
[TBL] [Abstract][Full Text] [Related]
20. Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis.
Speight RA; Nicolle A; Needham SJ; Verrill MW; Bryon J; Panter S
J Clin Oncol; 2013 Jun; 31(16):e245-7. PubMed ID: 23610110
[No Abstract] [Full Text] [Related]
[Next] [New Search]
